180 Life Sciences Corp. (NASDAQ: ATNF or the "Company"),
a clinical-stage biotechnology company with its lead indication in
Phase 2b/3, focused on the development of novel drugs that fulfill
unmet needs in inflammatory diseases, fibrosis and pain, today
announced the continued expansion of its IP portfolio.
180 Life Sciences is an applicant and licensee of a broad and
growing patent portfolio for three major drug platforms in the
areas of inflammation, fibrosis and pain. The patent portfolio
covers 16 patent families with 42 patents issued and 32 pending in
several important jurisdictions, including the United States,
Canada, Europe, Australia, Japan and China.
On November 20, 2020, the Company received a notice from the
USPTO that it will publish application 62/722,263 “Method of
treating frozen shoulder using an il-33/TNF bispecific antibody”.
The patent application is a continuation of US Patent No.
10,500,2730. Once the patent is granted, it will be assigned patent
number US-2020-0338193-A 1. This is an additional part of a
family of patents the Company has in its extensive patent
portfolio.
The Company also received a notice of acceptance for its US
patent, “Method of treating early stage Dupuytren's Disease”, with
the application number 16/089,234 filed September 27,
2018. Publication date is expected to occur on February 11,
2020.
Additionally, the Company received notification that the EU has
granted its application number 15726740.2, which was filed on
August 29, 2016.
The EU patent will be granted Dec 9, 2020, thereafter the
Company chooses where in the EU it wishes to validate the patent.
The Company has decided the following countries with the date of
publication of the grant, no later than March 9, 2021: Austria,
Belgium, Germany, Finland, France, Iceland, Ireland,
Italy, Netherlands, Norway, Spain, Sweden, Switzerland,
Liechtenstein, and United Kingdom.
The Company’s patent portfolio consists of three main sets of
IP, which correspond to the respective program.
Anti-TNF PlatformPatent families:
11Number of patents:
36 Number of patent applications:
25Lifespan:
Between
February 2031 and February 2036
SCA PlatformPatent families:
2Number of patents:
4*Number of patent applications:
3Lifespan:
April 2035**
* one will be granted as noted above on Dec 9, 2020** Expiry of
EU patent to be granted to be shown on grant date
α7nAChRPatent families:
3Number of patents:
2Number of patent applications:
3Lifespan:
2028
Other recent filings and grants include:
- Granted: January
14, 2020 Chinese patent ZL201580020978.7 for SCA: cyclohexenyl
compounds, compositions comprising them and uses.
- Filed: April 22,
2020 US patent application 62/704,121 SCA: bioactive
phenolate ionic complexes.
- Granted: June 2,
2020 US patent 10669334 treatment for Dupuytren’s Disease.
- Filed: September 1, 2020 Hong Kong
patent application 62020001194.3 for method of treating
systemic fibrotic disorders using an IL-33/TNF bispecific
antibody.
The Company’s patent portfolio is made up of both its own IP and
exclusive worldwide licenses, with, Oxford University Innovation
Limited, The Kennedy Trust for Rheumatology Research University of
Oxford, Stanford University, and the Hebrew University.
“The issuance of these additional patent assets
significantly strengthens the IP portfolio governing our lead
program,” said Dr. James Woody, CEO of 180 Life Sciences, “We are
committed to broadening our global patent estate as we continue to
expand our internal pipeline and increase patient access to
innovative therapies. Having these most recent patents awarded,
particularly in the EU, is important as it provides validation in
the 12 largest countries in the EU, including the UK, and provides
the platform to be able to expand clinical trials,
commercialization and partnering efforts throughout Europe.”
About 180 Life Sciences Corp.
180 Life Sciences Corp. is a clinical-stage biotechnology
company focused on the development of novel drugs that fulfill
unmet needs in inflammatory diseases, fibrosis and pain by
leveraging the combined expertise of luminaries in therapeutics
from Oxford University, the Hebrew University and Stanford
University. 180 Life Sciences is leading the research into solving
one of the world’s biggest drivers of disease – inflammation. The
Company is driving groundbreaking studies into clinical programs,
which are seeking to develop novel drugs addressing separate areas
of inflammation for which there are no effective therapies. The
Company’s primary platform is a novel program to treat fibrosis
using anti-TNF (tumor necrosis factor), with its lead program in
phase 2b/3 clinical trials.
Forward-Looking StatementsThis press release
includes "forward-looking statements", including information about
management’s view of the Company’s future expectations, plans and
prospects, within the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995 (the “Act”). Words such as
“expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,”
“believes,” “predicts,” “potential,” “continue” and similar
expressions are intended to identify such forward-looking
statements. These forward-looking statements involve significant
risks and uncertainties that could cause the actual results to
differ materially from the expected results and, consequently, you
should not rely on these forward-looking statements as predictions
of future events. These forward-looking statements and factors that
may cause such differences include, without limitation, statements
relating to the continued listing of the Company on The NASDAQ
Stock Market; expectations regarding the capitalization, resources
and ownership structure of the Company; expectations with respect
to future performance, growth and anticipated acquisitions; the
ability of the Company to execute its plans to develop and market
new drug products and the timing and costs of these development
programs; estimates of the size of the markets for its potential
drug products; potential litigation involving the Company or the
validity or enforceability of the intellectual property of the
Company; global economic conditions; geopolitical events and
regulatory changes; access to additional financing, and the
potential lack of such financing; and the Company’s ability to
raise funding in the future and the terms of such funding. These
risk factors and others are included from time to time in documents
the Company files with the Securities and Exchange Commission,
including, but not limited to, its Form 10-Ks, Form 10-Qs and Form
8-Ks, as well as in the definitive proxy statement/prospectus that
the Company filed in connection with the recent merger. These
reports and filings are available at www.sec.gov. All subsequent
written and oral forward-looking statements concerning the Company,
the transactions described herein or other matters and attributable
to the Company or any person acting on its behalf are expressly
qualified in their entirety by the cautionary statements above.
Readers are cautioned not to place undue reliance upon any
forward-looking statements, which speak only as of the date made.
The forward-looking statements included in this press release are
made only as of the date hereof. The Company cannot guarantee
future results, levels of activity, performance or achievements.
Accordingly, you should not place undue reliance on these
forward-looking statements. The Company does not undertake or
accept any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statement to reflect
any change in its expectations or any change in events, conditions
or circumstances on which any such statement is based, except as
otherwise provided by law.
Investors:
Jason AssadDirector of IR180 Life Sciences
Corp678-570-6791Jason@180lifesciences.com
Media Relations:
David SchullDavid.Schull@russopartnersllc.com (212) 845-4271
Eric AndoEric.Ando@russopartnersllc.com (646) 218-4604
180 Life Sciences (NASDAQ:ATNF)
Historical Stock Chart
From Aug 2024 to Sep 2024
180 Life Sciences (NASDAQ:ATNF)
Historical Stock Chart
From Sep 2023 to Sep 2024